MedPath

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Recruiting
Conditions
Refractory Mycosis Fungoides
Recurrent Mycosis Fungoides
Stage II Mycosis Fungoides
Stage III Mycosis Fungoides
Stage I Mycosis Fungoides
Interventions
Other: Quality-of-Life Assessment
Other: Objective Grading of Skin Findings
Registration Number
NCT02702310
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Brief Summary

This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement (relapsed). Radiation therapy uses high energy electrons to kill tumor cells and shrink tumors. Rotisserie technique is a method in which the patient receives total skin electron therapy while standing on a rotating platform. Giving low dose total skin electron therapy using rotisserie technique may kill tumor cells, while having fewer side effects, and may allow therapy to be repeated in future if clinically indicated.

Detailed Description

PRIMARY OBJECTIVES:

I. To assess the skin-related quality of life using an established method (Skindex-29), with comparisons made between pre-treatment and each of follow-up post-treatment skin assessments.

II. To assess the durability of response using an established method (modified Severity-Weight Assessment \[mSWAT\] tool), with comparisons made between pre-treatment and each of follow-up post-treatment skin assessments.

III. To determine side effect profile for low dose total skin electron therapy (TSE) for mycosis fungoides administered via rotisserie technique.

OUTLINE:

The investigational portion of this research study involves collecting quality of life (QOL) questionnaire data and objective measurements of patients' skin responses, which are obtained by the radiation oncologist during the patient's standard of care radiation treatment planning. Patients will also undergo standard of care low-dose total skin electron therapy for under 1 hour daily on days 10-21.

After completion of study treatment, patients are followed up at 6 and 12 weeks, and then every 3 months thereafter.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Biopsy confirmed mycosis fungoides stage IB-IIIA
  • Skin manifestations of mycosis fungoides that are refractory to or have relapsed on at least one prior therapy, which may include topical steroids
  • Life expectancy > 6 months
Exclusion Criteria
  • Serious medical condition that would make treatment unsafe
  • Pregnant or lactating patient

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Quality of Life/ Grading Skin FindingsQuality-of-Life AssessmentPatients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
Quality of Life/ Grading Skin FindingsObjective Grading of Skin FindingsPatients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
Primary Outcome Measures
NameTimeMethod
Change in skin-related quality of life assessed by Skindex-29Baseline to up to 3 years

Skindex-29 is a validated quality of life questionnaire to help quantify how mycosis fungoides may affect one's quality of life on a day to day basis, including emotional impact of the skin disease.

Secondary Outcome Measures
NameTimeMethod
Incidence of side effects of low dose total skin electron therapy administered via rotisserie techniqueUp to 3 years

The patient will be closely monitored by the radiation oncologist during treatment, with at least 2-3 visits while patient is on treatment. Side effects will be documents in patient medical records.

Change in the durability of response assessed by mSWAT toolBaseline to up to 3 years

mSWAT is the Modified Severity Weighted Assessment Tool used by the radiation oncologist during complete physical examination to quantify skin findings of patches, plaques, and tumors in all regions of the body; this would help the radiation oncologist and dermatologist to better follow the response to treatment.

Trial Locations

Locations (1)

Vanderbilt-Ingram Cancer Center

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath